EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease

Nan Jiang, Yan-Lun Gu, Huang Kuang iD, Zhao Cui, Ming-Hui Zhao iD, Xiao-Cong Pang, Xiao-Yu Jia

International Journal of Molecular Sciences · 27.05.2026 · 27 (11) · 4810

DOI: 10.3390/ijms27114810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.05.2026. Verfasst von Nan Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. Hauptthemen laut MEDLINE: Anti-Glomerular Basement Membrane Disease, Butyric Acid, Peptides, Collagen Type IV. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The non-collagenous domain 1 of the α3 chain of type IV collagen (α3(IV)NC1) is the primary autoantigen in anti-glomerular basement membrane (anti-GBM) disease. We previously developed a modified antigen-specific peptide, m-P14, derived from the nephritogenic epitope α3127–148, which ameliorated experimental anti-GBM nephritis. However, its short half-life limits clinical translation. This study evaluated a butyrate-conjugated derivative (m-P14-BA) to improve pharmacokinetic properties while preserving therapeutic efficacy. M-P14-BA and m-P14 were administered to α3127–148 immunized Wistar Kyoto rats in early and late treatment settings. Renal injury parameters and intrarenal inflammation were assessed, and pharmacokinetic profiles were evaluated following intraperitoneal administration in beagle dogs. M-P14-BA reduced proteinuria, crescent formation, glomerular IgG deposition, complement activation, and inflammatory cell infiltration, with overall efficacy comparable to m-P14 in early treatment settings. In late treatment settings, m-P14-BA was associated with a significant improvement in blood urea nitrogen levels and modest reductions in proteinuria and histopathological injury. Butyrate conjugation markedly improved pharmacokinetics, prolonging plasma elimination half-life by approximately 2.8-fold and increasing systemic exposure nearly fourfold. These pharmacokinetic improvements were associated with maintained therapeutic efficacy at a reduced dose, with 10 mg/kg m-P14-BA achieving effects broadly similar to those observed with 30 mg/kg m-P14. In summary, butyrate conjugation improves the pharmacokinetic profile of an antigen-specific therapeutic peptide while preserving therapeutic activity, suggesting a potential strategy to enhance the translational feasibility of peptide-based immunotherapy in anti-GBM disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Glomerular Basement Membrane DiseaseButyric AcidPeptidesCollagen Type IVAnimalsRatsDogsRats, Inbred WKYMaleAutoantigensProteinuriaAutoantibodies

Stichwörter der Autor:innen

anti-glomerular basement membrane diseaseglomerulonephritisimmunotherapypeptidespharmacokinetics

Substanzen

Butyric AcidPeptidesCollagen Type IVtype IV collagen alpha3 chainAutoantigensAutoantibodies

Autor:innen und Institutionen

  • Renal Division, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
  • Institute of Nephrology, Peking University, Beijing 100034, China.
  • Key Laboratory of Renal Disease, Ministry of Health of China, Beijing 100034, China.
  • Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing 100034, China.
  • Department of Pharmacy, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xue Yuan Rd. 38, Haidian District, Beijing 100191, China.

ORCID-Profile: Huang Kuang, Ming-Hui Zhao

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation

Zitieren

APA

Jiang, N., Gu, Y. L., Kuang, H., Cui, Z., Zhao, M. H., Pang, X. C., & Jia, X. Y. (2026). Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease. International Journal of Molecular Sciences, 27(11), 4810. https://doi.org/10.3390/ijms27114810

Vancouver

Jiang N, Gu YL, Kuang H, Cui Z, Zhao MH, Pang XC, et al. Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease. International Journal of Molecular Sciences. 2026;27(11):4810. doi:10.3390/ijms27114810

BibTeX
@article{Jiang2026,
  author = {Jiang, Nan and Gu, Yan-Lun and Kuang, Huang and Cui, Zhao and Zhao, Ming-Hui and Pang, Xiao-Cong and Jia, Xiao-Yu},
  title = {Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4810},
  doi = {10.3390/ijms27114810}
}
Kostenlos starten →